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Amyotrophic lateral sclerosis (ALS) was first depicted
by Charcot in the 19th century1. This disorder affects
anterior horn cells of the spinal cord and the motor
cranial nuclei. It will cause muscle weakness, disability
and eventually death, with a median survival of 3 to 5
years. ALS is relatively rare, although it is the third com-
monest neurodegenerative disease after Alzheimer’s
and Parkinson’s diseases2,3. ALS has an annual incidence
of 1–3 cases in 100,000 population worldwide4. Asym-
metric limb weakness is the most common initial pres-
entation of ALS (80%). It is relatively rare that respiratory
muscle weakness presents as the initial symptom of ALS.
It accounts for only 1–3% of all ALS cases5. How to iden-
tify the respiratory onset of ALS in the beginning is worth
investigating and discussing. We report a 75-year-old
female with an unknown cause of acute respiratory
failure.
Case Report
A 75-year-old female with a history of hypertension
was discharged 1 month previously from another hos-
pital after treatment for hypertrophy of the thyroid
gland with external compression of the trachea, hyper-
thyroidism, diffuse bronchiolitis, and bronchiectasis. She
was brought to our emergency department with dysp-
nea on September 8, 2007. Computed tomography did
not show any lung mass, and lung function tests showed
restrictive lung disease in our hospital. After treatment
with anti-hyperthyroidism medicine, steroids and anti-
biotics, her condition improved and she was discharged
on October 2, 2007.
On the night of discharge, she was brought to our
emergency department because of cold sweats, chest
tightness and progressive shortness of breath. Electro-
cardiogram and cardiac enzymes were all within normal
limits. A chest X-ray showed cardiomegaly, atheroscle-
rosis, and increased lung marking over both lung
fields. After ipratropium and salbutamol inhalation
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and intravenous furosemide, her condition improved
and she was discharged the next day. Unfortunately,
she returned to our emergency department again on
October 4, 2007 because of exacerbation of dyspnea. Her
body temperature was 36°C, pulse rate was 105/minute,
respiratory rate was 30/minute, and blood pressure was
133/77 mmHg. Physiologic monitoring and an oxygen
mask with 100% oxygen were applied. She was alert
but could not talk. Physical examination showed clear
breathing sounds with a regular heartbeat. Ipratropium
and salbutamol inhalation and intravenous hydrocorti-
sone were administered immediately. The initial arte-
rial blood gas showed: pH, 7.25; PCO2, 101.1mmHg; PO2,
101.8 mmHg; HCO3, 34.9 mmol/L; and O2 saturation,
96.2%. However, she was drowsier after initial treatment,
and subsequent follow-up of arterial blood gas showed
an increase in CO2 retention of up to 143 mmHg. Due
to severe respiratory acidosis with CO2 retention, an
endotracheal tube was inserted for mechanical venti-
lation. During admission, the patient’s consciousness
became clearer after correction of the CO2 level. The
patient was alert with isocoric pupils and with normal
light reflex. Extraocular movement was intact without
limitation and the corneal reflex was normal. Muscle
power of the bilateral extremities was around grade 4+
without any sensory deficit or pain. There were upper
motor neuron (UMN) signs with increased deep tendon
reflex and jaw jerk, lower motor neuron (LMN) signs
with muscle atrophy of the four limbs, and fasciculation
of the tongue. Brain and cervical magnetic resonance
imaging did not show any abnormality. Acetylcholine
receptor antibody was negative. Serum thyrotropin, free
thyroxine, corticotropin, cortisol and creatine kinase
levels were all within normal limits. Paraneoplastic syn-
drome was once suspected, but tumor markers, includ-
ing α-fetoprotein, CA-125, CA-153, carcinoembryonic
antigen, CA-199 and squamous cells carcinoma antigen,
were all negative. Vitamin B12 and folic acid levels
were normal. Cerebrospinal fluid was clear in appear-
ance with a normal cell count, but mildly elevated pro-
tein was found. Cerebrospinal fluid electrophoresis was
done and no oligoclonal bands were detected.
The endotracheal tube was removed smoothly after
improvement in the patient’s condition. A bilevel pos-
itive pressure device and oxygen mask were used alter-
nately. A sensory nerve conduction study (NCS) showed
normal results. A motor NCS showed reduced compound
motor action potentials of all sampled nerves and nor-
mal conduction velocity of all sampled nerves without
conduction block. The electromyography (EMG) study
suggested neuropathic change rather than myopathy.
ALS was diagnosed; because of the need for long-
term noninvasive positive pressure ventilation support,
she was transferred to a respiratory care center for 
further care.
Discussion
The term ALS is derived from the combination of the
clinical finding of amyotrophy and the pathologic find-
ing of lateral sclerosis6–10. The hallmark of ALS is the
combination of UMN and LMN involvement6,11. The
UMN signs include hyperreflexia, spasticity, and patho-
logic reflexes such as a jaw jerk or Hoffman’s sign. The
LMN signs include weakness, atrophy, and fasciculations.
Extraocular muscles and bladder and anal sphincter
muscles typically are spared12. ALS has an age distribu-
tion that peaks in the seventh to eighth decade4. Ninety
percent of all ALS cases are sporadic, and the rest are
familial12. The only established risk factors for ALS are
age and family history.
Differences in site and segment of onset, pattern 
and speed of spread, and the degree of UMN and LMN
dysfunction produce a disorder that is extraordinarily
variable between individuals. Asymmetric limb weak-
ness is the most common initial presentation of ALS12.
It accounts for 80% of all ALS cases. The manifestations
are usually distal but gradually progress to involve the
more proximal muscles. Upper extremity onset of ALS
most often begins with hand weakness. Lower extremity
onset is most often heralded by foot drop. Bulbar ALS
onset is the next most common initial presentation (20%)
and often presents as dysarthria or dysphagia.
In contrast, respiratory muscle weakness is a rare
pattern of onset in ALS; it presents in only 1–3% of
patients5. Patients with respiratory muscle weakness
may initially complain of fatigue only but eventually
note shortness of breath triggered by decreasing levels
of activity or by lying flat. In addition, they may develop
disturbed nocturnal sleep with frequent awakenings
and excessive daytime sleepiness.
In our patient, diffuse bronchiolitis, bronchiectasis
and hyperthyroidism were found in another hospital.
She visited our hospital because of dyspnea. Bron-
chiectasis or congestive heart failure was suspected in
the beginning, so we gave her ipratropium and salbu-
tamol inhalation, and intravenous furosemide and
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hydrocortisone. However, dyspnea worsened and pro-
gressed to acute respiratory failure. Sensory examina-
tion including light touch, two-point discrimination,
vibration sensation, joint position perception, temper-
ature, and pain perception were checked and were all
normal. Muscle power in the bilateral extremities was
4+ on the Medical Research Council scale. Pain, ocular
dysmotility, ptosis, anal and bladder sphincter dysfunc-
tion, and tremor were absent in this patient. Both UMN
and LMN signs were detected. UMN signs with increased
deep tendon reflex and pathologic reflex, including jaw
jerk and Hoffman’s sign, LMN signs with muscle atrophy
in the four limbs, and fasciculation of the tongue were
found. Therefore, diseases with both UMN and LMN signs
could be the cause.
Because of her previous history of hyperthyroidism,
blood thyrotropin, free thyroxine, corticotropin and
cortisol levels were checked and were all within the
normal range. Brain and cervical magnetic resonance
imaging did not show any abnormality, so cervical
spondylosis, spinal cord compression or spinal tumor
was not the cause13. Cerebrospinal fluid examination
showed no central nervous system infection or inflam-
mation13. Acetylcholine receptor antibody was checked
to exclude the possibility of neuromuscular junction
disorder such as myasthenia gravis, which also turned
out to be negative. Neither did the patient present with
ptosis or diurnal variation of symptoms, and myasthe-
nia gravis was excluded14,15. The EMG and NCS revealed
denervated and re-innervated polyphasic motor unit
action potentials in all sampled muscles, suggesting neu-
ropathic change rather than myopathy, so myopathy
was excluded. Diseases of the brain, spinal cord, neuro-
muscular junction and muscle had been excluded.
According to the patient’s neurologic examination
and clinical course, ALS or multifocal motor neuropathy
with conduction block should be considered. Multifocal
motor neuropathy with conduction block usually man-
ifests slowly with the mean age of onset between 20
and 50 years. In addition, deep tendon reflexes may be
absent or normal, and motor NCS should show conduc-
tion block. However, our patient was 75 years old; thus,
her deep tendon reflex was increased and the mode of
disease onset was very acute. Also, sensory NCS showed
normal results, and motor NCS showed reduced com-
pound motor action potentials in all sampled nerves
and normal conduction velocity in all sampled nerves
without conduction block. Therefore, multifocal motor
neuropathy with conduction block was excluded16,17.
This is an important finding, because multifocal motor
neuropathy with conduction block responds well to
immunoglobulin.
EMG and NCS are most helpful when clinical evidence
supporting the diagnosis of ALS is limited or conflicting.
The EMG findings in ALS contain features of acute and
chronic denervation18,19. Signs of active denervation in-
clude fibrillation potentials and positive sharp waves,
whereas signs of chronic denervation include large
amplitude, long duration, and polyphasic motor unit
potentials. Sensory and motor NCS are often normal in
ALS, although compound motor action potential ampli-
tudes may be reduced in severely atrophic and dener-
vated muscles18–20. Motor conduction block should not
be observed. In our case, EMG and NCS supported the
diagnosis of ALS. In summary, based on the presence
of UMN and LMN symptoms, NCS and EMG reports, and
the absence of an alternative explanation, ALS was
diagnosed.
In the study of Shoesmith et al.5, the survival time
of patients with respiratory onset ALS was not signifi-
cantly different from general ALS in a large case series.
Thus, they concluded that ALS with respiratory onset
does not necessarily mean a rapidly progressive course.
The mean age of symptom onset in patients with respi-
ratory onset was slightly greater than the average age
of ALS reported in the literature. Only 14% of these
individuals present acutely and require emergency
intubation5.
No cure for ALS is known at present. Medical care 
in ALS is primarily palliative. Riluzole is the only drug
licensed for the treatment of ALS. It is designed as 
a specific glutamate antagonist and can prolong 
tracheostomy-free survival by 3–6 months21. Respiratory
failure will be anticipated in all ALS patients. Current
recommendations are that noninvasive positive pres-
sure ventilation should be offered to any patient with
respiratory symptoms and vital capacity of less than
50%. Noninvasive positive pressure ventilation will 
improve survival in ALS, reduce the work of breathing,
promote good gas exchange, and improve quality of
sleep22,23. Some patients may require ventilatory support
for increasing periods while awake or even continuously
and may choose to undergo tracheostomy24. Trache-
ostomy may lead to prolonged survival in the face of
severe disability. End of life should be clarified early.
Although neurologists readily recognize ALS and its
variants, about 10% of patients are misdiagnosed and
delays in diagnosis are common. The delay from onset
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of the disease to confirmation of the diagnosis can
vary between 13 and 18 months25. No single diagnostic
test can confirm or entirely exclude the diagnosis of
ALS. A careful history and physical and neurologic ex-
aminations are always important, especially when the
full clinical features are not manifested.
In conclusion, acute respiratory failure is often a late
complication of ALS, but it could occur as an initial
manifestation of ALS onset and is easily misdiagnosed.
Confirming the diagnosis of ALS may initially be difficult
until the full clinical features are manifested. It is a good
reminder that while such a complaint is common, we
should be alert for the occasional patient who presents
with an unexpected disorder. Therefore, a careful history
and physical and neurologic examination are important,
particularly in the elderly or those who have a family
history of ALS.
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